HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Similar But Not Identical: Plaque Psoriasis Exacerbation in a Patient With Crohn's Disease After Switching From CT-P13 to SB2 Infliximab Biosimilar.

AuthorsCristiano Pagnini, Maria Carla Di Paolo, Giulia De Angelis, Federica Torcolacci, Michele Milano, Daniela Trinca, Roberto Porciello, Maria Giovanna Graziani
JournalInflammatory bowel diseases (Inflamm Bowel Dis) Vol. 26 Issue 8 Pg. e83-e84 (07 17 2020) ISSN: 1536-4844 [Electronic] England
PMID32458993 (Publication Type: Case Reports, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Biosimilar Pharmaceuticals
  • CT-P13
  • SB2 infliximab
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (administration & dosage)
  • Biosimilar Pharmaceuticals (administration & dosage, adverse effects)
  • Crohn Disease (complications, drug therapy)
  • Disease Progression
  • Drug Substitution (adverse effects)
  • Humans
  • Infliximab (administration & dosage, adverse effects)
  • Male
  • Medical Illustration
  • Psoriasis (chemically induced, complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: